Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Rubenstrunk A, et al. Among authors: hanf r. Biochim Biophys Acta. 2007 Aug;1771(8):1065-81. doi: 10.1016/j.bbalip.2007.02.003. Epub 2007 Feb 24. Biochim Biophys Acta. 2007. PMID: 17428730 Review.
The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.
Hanf R, Millatt LJ, Cariou B, Noel B, Rigou G, Delataille P, Daix V, Hum DW, Staels B. Hanf R, et al. Diab Vasc Dis Res. 2014 Nov;11(6):440-7. doi: 10.1177/1479164114548027. Epub 2014 Sep 11. Diab Vasc Dis Res. 2014. PMID: 25212694 Free article.
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group. Ratziu V, et al. Among authors: hanf r. Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11. Gastroenterology. 2016. PMID: 26874076 Free article. Clinical Trial.
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, Magnanensi J, Hajji Y, Brozek J, Roudot A, Staels B, Hum DW, Megnien SJ, Hosmane S, Dam N, Chaumat P, Hanf R, Anstee QM, Sanyal AJ. Harrison SA, et al. Among authors: hanf r. Lancet Gastroenterol Hepatol. 2020 Nov;5(11):970-985. doi: 10.1016/S2468-1253(20)30252-1. Epub 2020 Aug 5. Lancet Gastroenterol Hepatol. 2020. PMID: 32763196 Clinical Trial.
Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes.
Chávez-Talavera O, Wargny M, Pichelin M, Descat A, Vallez E, Kouach M, Bigot-Corbel E, Joliveau M, Goossens JF, Le May C, Hadjadj S, Hanf R, Tailleux A, Staels B, Cariou B. Chávez-Talavera O, et al. Among authors: hanf r. Metabolism. 2020 Feb;103:154042. doi: 10.1016/j.metabol.2019.154042. Epub 2019 Nov 27. Metabolism. 2020. PMID: 31785259
Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.
Colin S, Briand O, Touche V, Wouters K, Baron M, Pattou F, Hanf R, Tailleux A, Chinetti G, Staels B, Lestavel S. Colin S, et al. Among authors: hanf r. Eur Heart J. 2013 Aug;34(32):2566-74. doi: 10.1093/eurheartj/ehs227. Epub 2012 Jul 26. Eur Heart J. 2013. PMID: 22843443 Free PMC article.
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R. Staels B, et al. Among authors: hanf r. Hepatology. 2013 Dec;58(6):1941-52. doi: 10.1002/hep.26461. Epub 2013 Oct 29. Hepatology. 2013. PMID: 23703580 Clinical Trial.
Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.
Cariou B, Hanf R, Lambert-Porcheron S, Zaïr Y, Sauvinet V, Noël B, Flet L, Vidal H, Staels B, Laville M. Cariou B, et al. Among authors: hanf r. Diabetes Care. 2013 Oct;36(10):2923-30. doi: 10.2337/dc12-2012. Epub 2013 May 28. Diabetes Care. 2013. PMID: 23715754 Free PMC article. Clinical Trial.
Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.
Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH; LITMUS systematic review team(†). Vali Y, et al. J Hepatol. 2020 Aug;73(2):252-262. doi: 10.1016/j.jhep.2020.03.036. Epub 2020 Apr 8. J Hepatol. 2020. PMID: 32275982 Free article.
PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke.
Ouk T, Potey C, Laprais M, Gautier S, Hanf R, Darteil R, Staels B, Duriez P, Bordet R. Ouk T, et al. Among authors: hanf r. Fundam Clin Pharmacol. 2014 Jun;28(3):294-302. doi: 10.1111/fcp.12035. Epub 2013 May 23. Fundam Clin Pharmacol. 2014. PMID: 23701370
33 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback